Study to Assess the Safety and Efficacy of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)

NCT01253512 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke

Interventions

DRUG: THR-18
DRUG: Placebo

Sponsor

Thrombotech Ltd.